Prognosis

Adoption and Innovation of AI Tech in the Healthcare Sector

Retrieved on: 
Wednesday, December 22, 2021
Newton, Crypto, Clean technology, Technology, Sale, MRI, Mining, Climate change, ICT, COVID-19, RSNA, Learning, Philips, Radiology, Play, Risk, Patient, GE Healthcare, Water, IOT, Government, Radiological Society of North America, Renewable energy, Magnetic resonance, Artificial intelligence, Social media, Innovation, IR, Marketing, Life, Nursing, Efficiency, Diagnosis, Disclosure, Radio, Solution, General Electric, Move, OTC Markets Group, Safety, Publishing, Cannabis, News, Digital, Market, Magnetic resonance imaging, General manager, Pressure, Policy, Letter, Intelligence, Virtual reality, Prognosis, Research, Lung cancer, GBT, Partnership, Medical device, Pharmaceutical industry, Medical imaging, Mobile phone, Metaverse, AI, Health care

Artificial Intelligence (AI) technologies have achieved near ubiquity in everyday life and in few places is this more true than in the healthcare sector.

Key Points: 
  • Artificial Intelligence (AI) technologies have achieved near ubiquity in everyday life and in few places is this more true than in the healthcare sector.
  • Though the use of AI in healthcare is not a new notion, its application in the COVID-19 outbreak situation has proven its prospects in the sector.
  • The AI tools are rapidly being used to detect & diagnose the virus and retort to the outbreak through personalized information and learning.
  • While COVID-19 has undoubtedly amplified adoption and innovation of artificial intelligence technologies within the healthcare sector, AI is demonstrably well on its way to continue to develop as an integral part of the market after the pandemic.

Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics

Retrieved on: 
Monday, December 20, 2021
Heart, Heart failure, Prognosis, Investor, Exercise, Sale, Telephone, JI, Science, RTW, Risk, CEO, Hospital, Patient, Disease, Investment, Drug development, Partner (business rank), Systole, GLOBE, Partnership, Webcast, Pharmaceutical industry, LP, Cytokinetics

SOUTH SAN FRANCISCO, Calif., and SHANGHAI, China, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Ji Xing Pharmaceuticals Limited (JI XING), a biopharmaceutical company based in Shanghai and backed by RTW Investments, LP (RTW), today announced an expansion of their collaboration by entering into an exclusive license and collaboration agreement to develop and commercialize omecamtiv mecarbil for the proposed treatment of heart failure with reduced ejection fraction (HFrEF) in Greater China. In addition to the license and collaboration agreement with JI XING, Cytokinetics has also entered into Common Stock Purchase Agreements that provide for the sale and issuance to entities affiliated with RTW of 511,182 of shares of Cytokinetics common stock at a price per share of $39.125.

Key Points: 
  • We have been impressed by our productive partnership to date focused on aficamten and are pleased to expand our collaboration to now include omecamtiv mecarbil, said Joseph Romanelli, CEO of JI XING.
  • Despite the advancement of heart failure treatments in China, patients continue to need novel therapies to reduce the risk of disease.
  • Members of Cytokinetics senior management team will host a conference call and webcast today, December 20, at 8:30 AM Eastern Time.
  • Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements.

Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid Tumors

Retrieved on: 
Thursday, December 16, 2021
ACT, Forward-looking statement, Board of directors, Food, FDA, Prognosis, Survival rate, Breast, Company, African Americans, Board, Development, Doctor of Philosophy, Tumor microenvironment, Private Securities Litigation Reform Act, SAN, Treatment of lung cancer, IND, Biomarker, Woman, COVID-19, RECIST, Cancer, Breast cancer, Survival, Toxic shock syndrome, SEC, ROR1, TCR, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, Safety, Goal, Patient, BRCA1, Mutation, Program, Lung cancer, MD, TIL, GLOBE, NSCLC, CAR, AP-1, Sutphin Boulevard station (IND Queens Boulevard Line), Large-cell lung carcinoma, Pharmaceutical industry, Vaccine, Medical imaging, Birth control, Lyell, TNBC

LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) solid tumors.

Key Points: 
  • LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) solid tumors.
  • "We look forward to testing this first-generation technology platform in the clinic, thus specifically addressing the question of exhaustion as a barrier to successful cell therapy in solid tumors."
  • LYL797 is a novel, ROR1-targeted CAR T-cell product that incorporates genetic and epigenetic reprogramming technologies, Gen-R and Epi-R, to overcome barriers of CAR T-cell therapies in solid tumors.
  • Lyell is a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors.

Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Retrieved on: 
Thursday, December 16, 2021
U.S. Securities and Exchange Commission, FDA, Prognosis, Tipifarnib, AML, Company, The Cancer Genome Atlas, Population, KURA, SAN, Nasdaq, EGFR, Cancer, Survival, SEC, Head, Immunotherapy, Breakthrough therapy, Oncogene, Risk, NPM1, Research, Safety, Novartis, Patient, Cetuximab, Neoplasm, TCGA, Therapy, Security (finance), Patent, KMT2A, PI3K, GLOBE, HRAS, Drug resistance, PIK3CA, News, Pharmaceutical industry, HNSCC

SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced dose administration for the first patient in KURRENT, the Company’s Phase 1/2 clinical trial of tipifarnib in combination with alpelisib in patients with HRAS- and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC).

Key Points: 
  • Tipifarnib is Kuras farnesyl transferase inhibitor drug candidate currently in a registration-directed trial as a monotherapy in patients with HRAS mutant HNSCC.
  • Novartis alpelisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against the PI3K isoform.
  • Earlier this year, Kura announced a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with HNSCC whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification.
  • Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, accounting for more than 500,000 new cases each year.

Three New Articles Focus on COVID-19: Diagnosis and Risk Factors

Retrieved on: 
Thursday, December 16, 2021
Society, COVID, Waist, RNA, Prognosis, Death, Severe acute respiratory syndrome coronavirus 2, Experimental Biology and Medicine, SAGE, Child, RT, COVID-19, Experimental Biology and Medicine (Society for Experimental Biology and Medicine journal), Review, Emory University School of Medicine, Institute, Risk, Pediatrics, Research, Patient, CT, Obesity, Attention, Department, Experimental biology, Hyperglycemia, GLOBE, Abdominal obesity, Infection, Diabetes, Cohort study, Multisystem inflammatory syndrome, Manuscript, EBM, Pharmaceutical industry, Vaccine, Osteopontin, Endocrinology, Medicine

The Editor-in-Chief is currently handling manuscripts which focus on COVID to ensure that each paper undergoes a rapid yet thorough review.

Key Points: 
  • The Editor-in-Chief is currently handling manuscripts which focus on COVID to ensure that each paper undergoes a rapid yet thorough review.
  • Experimental Biology and Medicine recently published three articles focused on COVID-19.Reisner et al.
  • Finally, Khalangot et al (in press) analyze the risk of death in COVID-19 patients with diabetes and obesity.
  • If you are interested in submitting a manuscript for consideration or viewing other articles published in the journal, please visit http://ebm.sagepub.com .

Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, December 13, 2021
HER2, Lasofoxifene, Poster, Prognosis, ESR1, ER, CDK, Biology, Bone, Incidence, Chicago (franchise), Woman, Breast cancer, NASDAQ, Research, Safety, Patient, Neoplasm, Therapy, Drug development, Menopause, Fulvestrant, Metastasis, Mutation, Program, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., University, Ligand Pharmaceuticals, GLOBE, Duke University, Pharmaceutical industry, Medical imaging, AI, SERM

The symposium was held December 7-10 at the Henry B. Gonzalez Convention Center in San Antonio.

Key Points: 
  • The symposium was held December 7-10 at the Henry B. Gonzalez Convention Center in San Antonio.
  • The program aims to evaluate the safety and efficacy of lasofoxifene as a treatment option for breast cancer patients who develop AI resistance due to ESR1 mutations.
  • If proven in rigorously designed clinical trials, this could represent a significant leap forward in the treatment of metastatic breast cancer.
  • Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lamberts Pharmaceutical Division.

Genetron Health’s Social Contribution Campaign to Make Precision Medicine More Accessible

Retrieved on: 
Monday, December 13, 2021
Phrase, Forward-looking statement, Prognosis, Primary health care, Company, Workers Democratic Party, Radiation, Diagnosis, Hospital, Private Securities Litigation Reform Act, Chinese Peasants' and Workers' Democratic Party, Lung cancer, EGFR, AstraZeneca, GTH, Cancer, Entrepreneurship, NASDAQ, SEC, CEO, Research, Patient, Molecular biology, GLOBE, Classification, Sichuan University, Ministry, Precision medicine, Technology, Genetic testing, Non-small-cell lung carcinoma, Medical imaging, Pharmaceutical industry, NSCLC

As the sole corporate donor, Genetron Health will provide free genetic testing services (using its 8-gene lung cancer assay) for 10,000 Chinese lung cancer patients.

Key Points: 
  • As the sole corporate donor, Genetron Health will provide free genetic testing services (using its 8-gene lung cancer assay) for 10,000 Chinese lung cancer patients.
  • Meanwhile, identifying rare driver gene mutations is also crucial to the diagnosis and treatment of lung cancer.
  • This particular project will leverage 8-gene lung cancer assays and testing services provided by Genetron Health.
  • We hope that in the future, there will be more companies that are as enthusiastic about public welfare as Genetron Health is, and are committed to improving precision medicine accessibility.

OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia

Retrieved on: 
Monday, December 13, 2021
Biomarker, Interleukin 7, Severe acute respiratory syndrome coronavirus 2, T-cell acute lymphoblastic leukemia, University of Kiel, Prognosis, BCP, Degenerative disease, OSE, PD-1, Veloxis Pharmaceuticals, Fortification, Cancer, Nivolumab, ISIN, Vaccination, B cell, CD127, T-ALL, Mab, Inflammation, Immunotherapy, Schleswig-Holstein, Safety, Boehringer Ingelheim, GLOBE, ASH, Cytokine release syndrome, Partnership, Society, Autoimmune disease, COVID-19, CD19, Research, Tissue, Mnemos EP, Macrophage, Pancreatic cancer, Large-cell lung carcinoma, Poster, University Medical Center Schleswig Holstein, Lymphocytopenia, IL-7, Patient, Ulcerative colitis, Department, University Medical Center, Immune system, Acute lymphoblastic leukemia, Epitope, University, Pharmaceutical industry, Vaccine, Diagnosis, PDX

OSE-127 is a monoclonal immunomodulatory antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R) that induces a powerful antagonist effect on effector T lymphocytes.

Key Points: 
  • OSE-127 is a monoclonal immunomodulatory antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R) that induces a powerful antagonist effect on effector T lymphocytes.
  • Despite the favourable prognosis of BCP-ALL, relapse remains a clinical challenge and novel targeted immunotherapy options are urgently needed.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

UK Visual Effects Market Outlook: A USD 761.71 Million Market by 2028, Growing at a CAGR of 6% from 2021 to 2028. - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 15, 2021
TV and Radio, Entertainment, Film & Motion Pictures, Bruce High Quality Foundation, Prognosis, Ecosystem, Tablet, Moving Picture Company, Component, Geography, USD, Milk VFX, Porter's five forces analysis, HD, CAGR, Digital recording, VFX, Visual effects, Use, Technology, Application, Framestore

Visual Effects (VFX) Market was valued at USD 497.26 Million in 2020 and is projected to reach USD 761.71 Million by 2028, growing at a CAGR of 6.01% from 2021 to 2028.

Key Points: 
  • Visual Effects (VFX) Market was valued at USD 497.26 Million in 2020 and is projected to reach USD 761.71 Million by 2028, growing at a CAGR of 6.01% from 2021 to 2028.
  • Visual Effects (VFX) Market report provides a holistic evaluation of the market for the forecast period.
  • Visual Effects (VFX) Market study provides an outlook on the development of market in terms of revenue throughout the prognosis period.
  • Visual Effects (VFX) Market is highly fragmented with the presence of a large number of players in the U.K. Market.

Valemetostat Pivotal Data Shows Promising Response Rates in Patients with Adult T-Cell Leukemia/Lymphoma

Retrieved on: 
Saturday, December 11, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Annual general meeting, DXD, Prognosis, Research, NHL, Safety, Thought, Adult, Progression-free survival, ORR, Peripheral T-cell lymphoma, EZH2, Cancer, ADC, EZH1, ODD, Daiichi Sankyo, Death, Gene, Patient, Quality of life, Cardiovascular disease, PTCL, Enzyme, Laboratory, Pit additive, Program, Sustainable development, ATL, MHLW, Alpha, Lymphatic system, Technology, Vaccine, Pharmaceutical industry, Fine chemical, Wood drying, Silviculture, Mortar (masonry), Online gambling, Adult T-Cell Leukemia/Lymphoma, EZH1 and EZH2, the Phase 2 Study, Valemetostat, Daiichi Sankyo, ADULT T-CELL LEUKEMIA/LYMPHOMA, EZH1 AND EZH2, THE PHASE 2 STUDY, VALEMETOSTAT, DAIICHI SANKYO

Secondary endpoints include investigator-assessed ORR, best response in tumor lesions, complete remission rate, tumor control rate, time to response, duration of response, progression-free survival, overall survival and safety.

Key Points: 
  • Secondary endpoints include investigator-assessed ORR, best response in tumor lesions, complete remission rate, tumor control rate, time to response, duration of response, progression-free survival, overall survival and safety.
  • A total of 25 patients were enrolled in the study in Japan.
  • Valemetostat is a potential first-in-class dual inhibitor of EZH1 and EZH2 currently in clinical development in the Alpha portfolio of Daiichi Sankyo.
  • Valemetostat is an investigational medicine that has not been approved for any indication in any country.